NEU 6.41% $15.27 neuren pharmaceuticals limited

Share Price, page-5005

  1. 406 Posts.
    lightbulb Created with Sketch. 1236
    Agree, Bell Potter's analysis on Neuren is not worth looking at. Their models are full of incorrect data and as you have pointed out, over the last 7 years no matter what the model might say they always conclude valuation target = current share price + ~$2.

    And the only reason they increase their valuation is because the share price exceeds their previous low target.

 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.